Overview of the Nonclinical Development Strategies and Class-Effects of Oligonucleotide-Based Therapeutics

A Comprehensive Guide to Toxicology in Preclinical Drug Development

Volumn , Issue , 2013, Pages 647-664

  Younis, Husam S ^a   Templin, Michael ^b   Whitely, Lawrence O ^c   Kornbrust, Douglas ^d   Kim, Tae Won ^a   Henry, Scott P ^a  

^a ISIS PHARMACEUTICALS   (United States)

^b Marina Biotech   (United States)

^c PFIZER INC   (United States)

^d Preclinsight   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84883997458     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-387815-1.00026-5     Document Type: Chapter

References (79)

1. Grillone L.R., Lanz R. Fomivirsen. Drugs Today 2001, 37(4):245-255.
2. Crooke S.T. Molecular mechanisms of action of antisense drugs. Biochim Biophys Acta 1999, 1489(1):31-44.
3. Cerritelli S.M., Crouch R.J. Ribonuclease H: the enzymes in eukaryotes. FEBS J 2009, 276(6):1494-1505.
4. Zamecnik P.C., Stephenson M.L. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci 1978, 75(1):280-284.
5. Wu H., Lima W.F., Zhang H., Fan A., Sun H., Crooke S.T. Determination of the role of the human RNase H1 in the pharmacology of DNA-like antisense drugs. J Biol Chem 2004, 279(17):17181-17189.
6. Bell D.A., Hooper A.J., Burnett J.R. Mipomersen, an antisense apolipoprotein B synthesis inhibitor. Expert Opin Investig Drugs 2011, 20(2):265-272.
7. Saad F., Hotte S., North S., Eigl B., Chi K., Czaykowski P., et al. Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel. Clin Cancer Res 2011, 17(17):5765-5773.
8. Brandt T.A., Crooke S.T., Ackermann E.J., Xia S., Morgan E.S., Liu Q., et al. ISIS 113715, A Novel PTP-1B Antisense Inhibitor, Improves Glycemic Control and Dyslipidemia and Increases Adiponectin Levels in T2DM Subjects Uncontrolled on Stable Sulfonylurea Therapy. Diabetes 2010, 59(suppl1):A84.
9. Liu Q., Bethune C., Dessouki E., Grundy J., Monia B.P., Bhanot S. ISIS-FXIRx, A novel and specific antisense inhibitor of Factor XI, caused significant reduction in FXI antigen and activity and increased aPTT without causing bleeding in healthy volunteers. Blood 2011, 118:209. (ASH Annual Meeting Abstracts).
10. Ecker J.R., Davis R.W. Inhibition of gene expression in plant cells by expression of antisense RNA. Proc Natl Acad Sci 1986, 83(15):5372-5376.
11. Fire A., Xu S., Montgomery M.K., Kostas S.A., Driver S.E., Mello C.C. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998, 391(6669):806-811.
12. Grimm D. Small silencing RNAs: state-of-the-art. Adv Drug Deliv Rev 2009, 61(9):672-703.
13. Rácz Z., Kaucsár T., Hamar P. The huge world of small RNAs: regulating networks of microRNAs. Acta Physiol Hung 2011, 98(3):243-251.
14. Melnyk C.W., Molnar A., Baulcombe D.C. Intercellular and systemic movement of RNA silencing signals. EMBO J 2011, 30(17):3553-3563.
15. Davidson B.L., McCray P.B. Current prospects for RNA interference-based therapies. Nat Rev Genet 2011, 12(5):329-340.
16. Jackson A.L., Burchard J., Schelter J., Chau B.N., Cleary M., Lim L., et al. Widespread siRNA 'off-target' transcript silencing mediated by seed.region sequence complementarity. RNA 2006, 12:1179-1187.
17. Shim M.S., Kwon Y.J. Efficient and targeted delivery of siRNA in vivo. FEBS J 2010, 277(23):4814-4827.
18. Esposito C.L., Catuogno S., de Franciscis V., Cerchia L. New insight into clinical development of nucleic acid aptamers. Discov Med 2011, 11(61):487-496.
19. Apte R.S. Pegaptanib sodium for the treatment of age-related macular degeneration. Expert Opin Pharmacother 2008, 9(3):499-508.
20. Vollmer J., Krieg A.M. Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists. Adv Drug Deliv Rev 2009, 61(3):195-204.
21. Levin A.A., Yu R.Y., Geary R.S. Basic Principles of the Pharmacokinetics of Antisense Oligonucleotide Drugs. Antisense Drug Technology: Principles, Strategies and Applications 2008, 183-216. Taylor and Francis, Boca Raton. S.T. Crooke (Ed.).
22. Eckstein F. Phosphorothioate oligodeoxynucleotides: what is their origin and what is unique about them?. Antisense Nucleic Acid Drug Dev 2000, 10:117-121.
23. Martin P. New access to 2′-O-alkylated ribonucleosides and properties of 2′-O-alkylated oligoribonucleotides. Helv Chim Acta 1995, 78:486-504.
24. Teplova M., Minasov G., Tereshko V., Inamati G., Cook P.D., Manoharan M., et al. Crystal structure and improved antisense properties of 2′-O-(2-methoxyethyl)-RNA. Nat Struct Biol 1999, 6:535-539.
25. Monia B.P., Lesnik E.A., Gonzalez C., Lima W.F., McGee D., Guinosso C.J., et al. Evaluation of 2′-modified oligonucleotides containing 2′-deoxy gaps as antisense inhibitors of gene expression. J Biol Chem 1993, 268:14514-14522.
26. Altmann K.H., Martin P., Dean N.M., Monia B.P. Second generation antisense oligonucleotides - inhibition of pkc-alpha and c-raf kinase expression by chimeric oligonucleotides incorporating 6′-substituted carbocyclic nucleosides and 2′-O-ethylene glycol substituted ribonucleosides. Nucleosides Nucleotides 1997, 16:917-926.
27. Seth P.P., Siwkowski A., Allerson C.R., Vasquez G., Lee S., Prakash T.P., et al. Short antisense oligonucleotides with novel 2′-4′ conformationally restricted nucleoside analogues show improved potency without increased toxicity in animals. J Med Chem 2009, 52:10-13.
28. Straarup E.M., Fisker N., Hedtjarn M., Lindholm M.W., Rosenbohm C., Aarup V., et al. Short locked nucleic acid antisense oligonucleotides potently reduce apolipoprotein B mRNA and serum cholesterol in mice and non-human primates. Nucleic Acids Res 2010, 38(20):7100-7111.
29. Amantana A., Iversen P.L. Pharmacokinetics and biodistribution of phosphorodiamidate morpholino antisense oligomers. Curr Opin Pharmacol 2005, 5:550-555.
30. Stein D., Foster E., Huang S.B., Weller D., Summerton J.A. Specificity comparison of four antisense types: Morpholino, 2′-O-Methyl RNA, DNA, and Phosphorothioate DNA. Antisense Nucleic Acid Drug Dev 1997, 7:151-157.
31. Arora V., Devi G.R., Iversen P.L. Neutrally charged phosphorodiamidate morpholino antisense oligomers: uptake, efficacy and pharmacokinetics. Curr Pharm Biotechnol 2004, 5:431-439.
32. Swayze E.E., Bhat B. The Medicinal Chemistry of Oligonucleotides. Antisense Drug Technology 2008, 143-182. Taylor and Francis, Boca Raton. S. Principles, S.T. Applications Crooke (Eds.).
33. Geary R.S., Yu R.Z., Siwkowski A., Levin A.A. Pharmacokinetic/Pharmacodynamic Properties of Phosphorothioate 2′-O-(2-Methoxyethyl)-Modified Antisense Oligonucleotides in Animals and Man. Antisense Drug Technology: Principles, Strategies and Applications 2008, 305-326. Taylor and Francis, Boca Raton. S.T. Crooke (Ed.).
34. Haringsma H.J., Li J.J., Soriano F., Kenski D.M., Flanagan W.M., Willingham A.T. mRNA knockdown by single strand RNA is improved by chemical modifications. Nucleic Acids Research 2012, 1-12. Jan 16.
35. Henry S.P., Monteith D., Kombrust D.J., Levin A.A. Effects of Intravenous Infusion of Phosphorothioate Oligonucleotides on Coagulation, Complement Activation and Hemodynamics. Nucleosides & Nucleotides 1997, 16(7-9):1673-1676.
36. Black L.E., Degeorge J.J., Cavagnaro J.A., Jordan A., Ahn C.H. Regulatory considerations for evaluating the pharmacology and toxicology of antisense drugs. Antisense Res Dev 1993, 3(4):399-404.
37. Black L.E., Farrelly J.G., Cavagnaro J.A., Ahn C.H., DeGeorge J.J., Taylor A.S., et al. Regulatory considerations for oligonucleotide drugs: updated recommendations for pharmacology and toxicology studies. Antisense Res Dev 1994, 4(4):299-301.
38. Geary R.S., Leeds J.M., Henry S.P., Monteith D.K., Levin A.A. Antisense oligonucleotide inhibitors for the treatment of cancer: 1. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotides. Anticancer Drug Des 1997, 12(5):383-393.
39. Yu R.Z., Geary R.S., Leeds J.M., Watanabe T., Moore M., Fitchett J., et al. Comparison of pharmacokinetics and tissue disposition of an antisense phosphorothioate oligonucleotide targeting human Ha-ras mRNA in mouse and monkey. J Pharm Sci 2001, 90(2):182-193.
40. Geary R.S., Yu R.Z., Levin A.A. Pharmacokinetics of phosphorothioate antisense oligodeoxynucleotides. Curr Opin Investig Drugs 2001, 2(4):562-573.
41. Gaus H.J., Owens S.R., Winniman M., Cooper S., Cummins L.L. On-line HPLC electrospray mass spectrometry of phosphorothioate oligonucleotide metabolites. Anal Chem 1997, 69(3):313-319.
42. Griffey R.H., Greig M.J., Gaus H.J., Liu K., Monteith D., Winniman M., et al. Characterization of oligonucleotide metabolism in vivo via liquid chromatography/electrospray tandem mass spectrometry with a quadrupole ion trap mass spectrometer. J Mass Spectrom 1997, 32(3):305-313.
43. Henry S.P., Kim T.W., Kramer-Strickland K., Zanardi T.A., Fey R.A., Levin A.A. Toxicological Properties of 2'-O-Methoxyethyl Chimeric Antisense Inhibitors in Animals and Man. Antisense Drug Technology: Principles, Strategies and Applications 2008, 327-363. Taylor and Francis, Boca Raton. S.T. Crooke (Ed.).
44. Henry S.P., Denny K.H., Templin M.V., Yu R.Z., Levin A.A. Effects of an antisense oligonucleotide inhibitor of human ICAM-1 on fetal development in rabbits. Birth Defects Res B Dev Reprod Toxicol 2004, 71(6):368-373.
45. Henry S.P., Denny K.H., Templin M.V., Yu R.Z., Levin A.A. Effects of human and murine antisense oligonucleotide inhibitors of ICAM-1 on reproductive performance, fetal development, and post-natal development in mice. Birth Defects Res B Dev Reprod Toxicol 2004, 71(6):359-367.
46. Gantier M.P., Tong S., Behlke M.A., Irving A.T., Lappas M., Nilsson U.W., et al. Rational design of immunostimulatory siRNAs. Mol Ther 2010, 18(4):785-795.
47. Lindow M., Vornlocher H.P., Riley D., Kornbrust D., Whiteley L.O., Kamens J., et al. Assessing unintended hybridization induced biological effects of oligonucleotides 2012, Submitted for publication.
48. Bilanges B., Stokoe D. Direct comparison of the specificity of gene silencing using antisense oligonucleotides and RNAi. Biochem J 2005, 388(Pt 2):573-583.
49. Khan A.A., Betel D., Miller M.L., Sander C., Leslie C.S., Marks D.S. Transfection of small RNAs globally perturbs gene regulation by endogenous microRNAs. Nat Biotechnol 2009, 27:549-555.
50. Cho Y.S., Kim M.K., Cheadle C., Neary C., Becker K.G., Cho-Chung Y.S. Antisense DNAs as multisite genomic modulators identified by DNA microarray. Proc Natl Acad Sci 2001, 98:9819-9823.
51. Fisher A.A., Ye D., Sergueev D.S., Fisher M.H., Shaw B.R., Juliano R.L. Evaluating the specificity of antisense oligonucleotide conjugates. A DNA array analysis. J Biol Chem 2002, 277:22980-22984.
52. Jackson A.L., Bartz S.R., Schelter J., Kobayashi S.V., Burchard J., Mao M., et al. Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol 2003, 21:635-637.
53. Ma Z., Li J., He F., Wilson A., Pitt B., Li S. Cationic lipids enhance siRNA-mediated interferon response in mice. Biochem Biophys Res Commun 2005, 330(3):755-759.
54. Zhang S., Zhao B., Jiang H., Wang B., Ma B. Cationic lipids and polymers mediated vectors for delivery of siRNA. J Control Release 2007, 123(1):1-10.
55. Levin A.A., Henry S.P., Monteith D., Templin M.V. Toxicity of Antisense Oligonucleotides. Antisense Drug Technology Principles, Strategies, and Applications 2001, 201-267. Marcel Dekker, NY. S.T. Crooke (Ed.).
56. Henry S.P., Geary R.S., Yu R., Levin A.A. Drug properties of second-generation antisense oligonucleotides: how do they measure up to their predecessors?. Curr Opin Investig Drugs 2001, 2(10):1444-1449.
57. Henry S.P., Novotny W., Leeds J., Auletta C., Kornbrust D.J. Inhibition of coagulation by a phosphorothioate oligonucleotide. Antisense and Nucleic Acid Drug Development 1997, 7:503-510.
58. Sheehan J.P., Lan H.C. Phosphorothioate oligonucleotides inhibit the intrinsic tenase complex. Blood 1998, 92(5):1617-1625.
59. Sheehan J.P., Thao P.M. Phosphorothioate oligonucleotides inhibit the intrinsic tenase complex by an allosteric mechanism. Biochemistry 2001, 40(16):4980-4989.
60. Jeter M.L., Ly L.V., Fortenberry Y.M., Whinna H.C., White R.R., Rusconi C.P., et al. RNA aptamer to thrombin binds anion- underbinding exosite-2 and alters protease inhibition by heparin-binding serpins. FEBS Lett 2004, 568(1-3):10-14.
61. Henry S.P., Giclas P.C., Leeds J., Pangburn M., Auletta C., Levin A.A., et al. Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: Potential mechanism of action. Journal of Pharmacology and Experimental Therapeutics 1997, 281(2):810-816.
62. Henry S.P., Beattie G., Yeh G., Chappel A., Giclas P., Mortari A., et al. Complement Activation is Responsible for Acute Toxicities in Rhesus Monkeys Treated with a Phosphorothioate Oligodeoxynucleotide. Int Immunopharmacol 2002, 2(12):1657-1666.
63. Sewell K.L., Geary R.S., Baker B.F., Glover J.M., Mant T.G., Yu R.Z., et al. Phase I trial of ISIS 104838, a 2′-methoxyethyl modified antisense oligonucleotide targeting tumor necrosis factor-alpha. Journal of Pharmacology and Experimental Therapeutics 2002, 303(3):1334-1343.
64. Watanabe T.A., Geary R.S., Levin A.A. Plasma Protein Binding of an Antisense Oligonucleotide Targeting Human ICAM-1 (ISIS 2302). Oligonucleotides 2006, 16(2):169-180.
65. Zanardi T.A., Han S.C., Jeong E.J., Rime S., Yu R.Z., Chakravarty K., et al. Assessment of Pharmacodynamics and Subchronic Toxicity in Mice and Monkeys of ISIS 388626, a Novel Second Generation Antisense Oligonucleotide that Targets the Human Sodium Glucose Cotransporter 2 (SGLT2) 2012, In preparation.
66. Devine D.V., Wong K., Serrano K., Chonn A., Cullis P.R. Liposome-complement interactions in rat serum: implications for liposome survival studies. Biochim Biophys Acta 1994, 1191(1):43-51.
67. Moghimi S.M., Hamad I. Liposome-mediated triggering of complement cascade. J Liposome Res 2008, 18(3):195-209.
68. Yacyshyn B.R., Chey W.Y., Goff J., Salzberg B., Baerg R., Buchman A.L., et al. Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease. Gut 2002, 51(1):30-36.
69. Kastelein J.J., Wedel M.K., Baker B.F., Su J., Bradley J.D., Yu R.Z., et al. Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation 2006, 114(16):1729-1735.
70. Chi K.N., Siu L.L., Hirte H., Hotte S.J., Knox J., Kollmansberger C., et al. A phase I study of OGX-011, a 2′-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer. Clinical Cancer Research 2008, 14(3):833-839.
71. Frank M.M., Fries L.F. The role of complement in inflammation and phagocytosis. Immunology Today 1991, 12(9):322-326.
72. Whitehead K.A., Langer R., Anderson D.G. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov 2009, 8(2):129-138.
73. Ozpolat B., Sood A.K., Lopez-Berestein G.J. Nanomedicine based approaches for the delivery of siRNA in cancer. Intern Med 2010, 267(1):44-53.
74. Esteller M. Non-coding RNAs in human disease. Nat Rev Genet 2011, 12(12):861-874.
75. Fichtlscherer S., Zeiher A.M., Dimmeler S. Circulating microRNAs: biomarkers or mediators of cardiovascular diseases?. Arterioscler Thromb Vasc Biol 2011, 31(11):2383-2390.
76. Zalts H., Shomron N. The impact of microRNAs on endocrinology. Pediatr Endocrinol Rev 2011, 8(4):354-362.
77. van Rooij E., Purcell A.L., Levin A.A. Developing microRNA therapeutics. Circulation Research 2012, 110:483-495.
78. Moulton H.M., Wu B., Jearawiriyapaisarn N., Sazani P., Lu Q.L., Kole R. Peptide-morpholino conjugate: a promising therapeutic for Duchenne muscular dystrophy. Ann N Y Acad Sci 2009, 1175:55-60.
79. van Deutekom J.C., Janson A.A., Ginjaar I.B., Frankhuizen W.S., Aartsma-Rus A., Bremmer-Bout M., et al. Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med 2007, 357(26):2677-2686.